2020 EAN: AJOVY (fremanezumab) treatment of refractory migraines is safe and effective
-
Last Update: 2020-05-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Teva Pharmaceuticals presents important data on® the treatment of migraines at the 2020 European Society of Neurology (EAN) Virtual ConferenceThe fremanezumab data includead a summary analysis of the FOCUS trial, the HALO onset migraine (EM) trial, and the HALO chronic migraine (CM) trialThe results showed that the headache smaller than baseline at 12 weeks in the fremanezumab group compared to placebomigraines can cause serious disease and financial burdensMore than 1 billion people worldwide are affected, and the United States and the European Union cost the disease $200 billion a yearThe cause of migraines is thought to be caused by a combination of environmental and genetic factorsAbout two-thirds of cases have genetic causesFluctuations in hormone levels may also be a factor: before puberty, there were slightly more boys than girls affected by migraines, but after that, two to three times more women than men were affected by migrainesThe exact cause of migraines is not yet known, but it is widely believed to be due to neurovascular disorders
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
